StreetInsider.com News Articles

StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 11:45:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Newron meets with FDA over US trial enrollment hold http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html <p>Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) held a Type A meeting with the U.S. Food and Drug Administration to discuss a hold on new patient enrollment at U.S. sites of its Phase III ENIGMA-TRS 2 study of evenamide, a drug candidate targeting treatment-resistant schizophrenia.</p> <p>The hold was first reported on April 29, 2026. According to a company statement, the face-to-face meeting addressed potential actions toward resolving the issues that led to the enrollment hold. Newron said it plans to propose changes to address the agency's concerns, as agreed with the FDA during the meeting.</p> <p>ENIGMA-TRS 2 is a 12-week, randomized, double-blind, http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html Thu, 02 Jul 2026 11:45:18 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron meets with FDA over US trial enrollment hold http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html <p>Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) held a Type A meeting with the U.S. Food and Drug Administration to discuss a hold on new patient enrollment at U.S. sites of its Phase III ENIGMA-TRS 2 study of evenamide, a drug candidate targeting treatment-resistant schizophrenia.</p> <p>The hold was first reported on April 29, 2026. According to a company statement, the face-to-face meeting addressed potential actions toward resolving the issues that led to the enrollment hold. Newron said it plans to propose changes to address the agency's concerns, as agreed with the FDA during the meeting.</p> <p>ENIGMA-TRS 2 is a 12-week, randomized, double-blind, http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html Thu, 02 Jul 2026 11:45:18 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron meets with FDA over US trial enrollment hold http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html <p>Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) held a Type A meeting with the U.S. Food and Drug Administration to discuss a hold on new patient enrollment at U.S. sites of its Phase III ENIGMA-TRS 2 study of evenamide, a drug candidate targeting treatment-resistant schizophrenia.</p> <p>The hold was first reported on April 29, 2026. According to a company statement, the face-to-face meeting addressed potential actions toward resolving the issues that led to the enrollment hold. Newron said it plans to propose changes to address the agency's concerns, as agreed with the FDA during the meeting.</p> <p>ENIGMA-TRS 2 is a 12-week, randomized, double-blind, http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html Thu, 02 Jul 2026 11:45:18 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron meets with FDA over US trial enrollment hold http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html <p>Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) held a Type A meeting with the U.S. Food and Drug Administration to discuss a hold on new patient enrollment at U.S. sites of its Phase III ENIGMA-TRS 2 study of evenamide, a drug candidate targeting treatment-resistant schizophrenia.</p> <p>The hold was first reported on April 29, 2026. According to a company statement, the face-to-face meeting addressed potential actions toward resolving the issues that led to the enrollment hold. Newron said it plans to propose changes to address the agency's concerns, as agreed with the FDA during the meeting.</p> <p>ENIGMA-TRS 2 is a 12-week, randomized, double-blind, http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html Thu, 02 Jul 2026 11:45:18 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron meets with FDA over US trial enrollment hold http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html <p>Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) held a Type A meeting with the U.S. Food and Drug Administration to discuss a hold on new patient enrollment at U.S. sites of its Phase III ENIGMA-TRS 2 study of evenamide, a drug candidate targeting treatment-resistant schizophrenia.</p> <p>The hold was first reported on April 29, 2026. According to a company statement, the face-to-face meeting addressed potential actions toward resolving the issues that led to the enrollment hold. Newron said it plans to propose changes to address the agency's concerns, as agreed with the FDA during the meeting.</p> <p>ENIGMA-TRS 2 is a 12-week, randomized, double-blind, http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html Thu, 02 Jul 2026 11:45:18 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron meets with FDA over US trial enrollment hold http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html <p>Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) held a Type A meeting with the U.S. Food and Drug Administration to discuss a hold on new patient enrollment at U.S. sites of its Phase III ENIGMA-TRS 2 study of evenamide, a drug candidate targeting treatment-resistant schizophrenia.</p> <p>The hold was first reported on April 29, 2026. According to a company statement, the face-to-face meeting addressed potential actions toward resolving the issues that led to the enrollment hold. Newron said it plans to propose changes to address the agency's concerns, as agreed with the FDA during the meeting.</p> <p>ENIGMA-TRS 2 is a 12-week, randomized, double-blind, http://www.streetinsider.com/FDA/Newron+meets+with+FDA+over+US+trial+enrollment+hold/26725670.html Thu, 02 Jul 2026 11:45:18 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Press+Releases/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Provides Update Following Type A Meeting With the FDA http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html <p class="bwalignc"> <b>Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US</b> </p><p class="bwalignc"> <b>Ad hoc announcement pursuant to Art. 53 LR</b> </p> <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54564264&newsitemid=20260702474678&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=500874017a21e1d54f80b615790762d3" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at http://www.streetinsider.com/Business+Wire/Newron+Provides+Update+Following+Type+A+Meeting+With+the+FDA/26725667.html Thu, 02 Jul 2026 11:45:00 -0400 0QOI A.06822034 NP5 NWRN O.00913260 O.20026344 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550 Newron Pharmaceuticals to Participate in June Investor Conferences http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html <p> MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2F&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Newron+Pharmaceuticals+S.p.A.&index=1&md5=19d6e5d388c43eccb05f9bd109c05ce5" shape="rect">Newron Pharmaceuticals S.p.A.</a> (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Stefan+Weber%2C+CEO&index=2&md5=7330a72ce6efa26edb6f180832e34fdd" shape="rect">Stefan Weber, CEO</a> and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newron.com%2Fabout-us%2Fsenior-management&esheet=54543500&newsitemid=20260528000168&lan=en-US&anchor=Roberto+Galli%2C+CFO&index=3&md5=380b0a2732fe232a63b87d1d3dee8a46" shape="rect">Roberto Galli, CFO</a>, will participate in the following investor conferences in June: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>, June 2–4, 2026, New York </li> <li> <b>H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference</b>, June 15–16, 2026, Virtual </li> </ul><p> At the Jefferies Global Healthcare Conference, members of the Newron management team http://www.streetinsider.com/Press+Releases/Newron+Pharmaceuticals+to+Participate+in+June+Investor+Conferences/26562571.html Thu, 28 May 2026 09:30:00 -0400 0QOI A.30352707 A.32240867 A.34461107 NP5 NWRN O.00913260 O.01860686 O.04672518 O.13103550